Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our IL ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

India achieves a milestone in dengue prevention. The DengiAll vaccine trial sees 70% participant enrollment. ICMR leads the ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development ...

A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally and remains a major public health burden. It is currently defined as FEV1/forced vital capacity (FVC) below ...

Clinical trials are the backbone of medical innovations, shaping the therapies and diagnostics that define modern healthcare. Designing and executing a successful trial involves more than scientific ...

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...